Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,371 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical characteristics, risk factors, and incidence of symptomatic coronavirus disease 2019 in a large cohort of adults living with HIV: a single-center, prospective observational study.
Inciarte A, Gonzalez-Cordon A, Rojas J, Torres B, de Lazzari E, de la Mora L, Martinez-Rebollar M, Laguno M, Callau P, Gonzalez-Navarro A, Leal L, Garcia F, Mallolas J, Mosquera M, Marcos MA, Ambrosioni J, Miro JM, Martinez E, Blanco JL; (on behalf the COVID-19 in HIV Investigators). Inciarte A, et al. Among authors: rojas j. AIDS. 2020 Oct 1;34(12):1775-1780. doi: 10.1097/QAD.0000000000002643. AIDS. 2020. PMID: 32773471 Free PMC article.
A maintenance 3-day-per-week schedule with the single tablet regimen efavirenz/emtricitabine/tenofovir disoproxil fumarate is effective and decreases sub-clinical toxicity.
Rojas J, Blanco JL, Sanchez-Palomino S, Marcos MA, Guardo AC, Gonzalez-Cordon A, Lonca M, Tricas A, Rodriguez A, Romero A, Miro JM, Mallolas J, Gatell JM, Plana M, Martinez E. Rojas J, et al. AIDS. 2018 Jul 31;32(12):1633-1641. doi: 10.1097/QAD.0000000000001843. AIDS. 2018. PMID: 29746294 Clinical Trial.
A 24-week pilot study of dual maintenance therapy with raltegravir and lamivudine.
de Lazzari E, Lonca M, Rojas J, Gonzalez-Cordon A, Blanch J, Inciarte A, Tricas A, Rodriguez A, Martinez-Rebollar M, Laguno M, Mallolas J, Sanchez-Palomino S, Plana M, Blanco JL, Martinez E. de Lazzari E, et al. Among authors: rojas j. AIDS. 2019 Oct 1;33(12):1891-1896. doi: 10.1097/QAD.0000000000002311. AIDS. 2019. PMID: 31335805 Clinical Trial.
Overview of SARS-CoV-2 infection in adults living with HIV.
Ambrosioni J, Blanco JL, Reyes-Urueña JM, Davies MA, Sued O, Marcos MA, Martínez E, Bertagnolio S, Alcamí J, Miro JM; COVID-19 in HIV Investigators. Ambrosioni J, et al. Lancet HIV. 2021 May;8(5):e294-e305. doi: 10.1016/S2352-3018(21)00070-9. Lancet HIV. 2021. PMID: 33915101 Free PMC article. Review.
[Acute outbreak of hepatitis C in human immunodeficiency virus-infected patients].
Martínez-Rebollar M, Mallolas J, Pérez I, González-Cordón A, Loncà M, Torres B, Rojas JF, Monteiro P, Blanco JL, Martínez E, Gatell JM, Laguno M. Martínez-Rebollar M, et al. Among authors: rojas jf. Enferm Infecc Microbiol Clin. 2015 Jan;33(1):3-8. doi: 10.1016/j.eimc.2014.05.013. Epub 2014 Aug 12. Enferm Infecc Microbiol Clin. 2015. PMID: 25124489 Spanish.
A randomized clinical trial comparing ritonavir-boosted lopinavir versus raltegravir each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection.
Leal L, León A, Torres B, Inciarte A, Lucero C, Mallolas J, Laguno M, Martínez-Rebollar M, González-Cordón A, Manzardo C, Rojas J, Pich J, Arnaiz JA, Gatell JM, García F; RALPEP Study Group. Leal L, et al. Among authors: rojas j. J Antimicrob Chemother. 2016 Jul;71(7):1987-93. doi: 10.1093/jac/dkw049. Epub 2016 Mar 18. J Antimicrob Chemother. 2016. PMID: 26994089 Clinical Trial.
A randomized clinical trial comparing ritonavir-boosted lopinavir versus maraviroc each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection.
Leal L, León A, Torres B, Inciarte A, Lucero C, Mallolas J, Laguno M, Martínez-Rebollar M, González-Cordón A, Manzardo C, Rojas J, Pich J, Arnaiz JA, Gatell JM, García F; MARAVIPEP Study Group. Leal L, et al. Among authors: rojas j. J Antimicrob Chemother. 2016 Jul;71(7):1982-6. doi: 10.1093/jac/dkw048. Epub 2016 Mar 18. J Antimicrob Chemother. 2016. PMID: 26994091 Clinical Trial.
Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression.
Rojas J, Blanco JL, Marcos MA, Lonca M, Tricas A, Moreno L, Gonzalez-Cordon A, Torres B, Mallolas J, Garcia F, Gatell JM, Martinez E. Rojas J, et al. J Antimicrob Chemother. 2016 Jul;71(7):1975-81. doi: 10.1093/jac/dkw078. Epub 2016 Mar 28. J Antimicrob Chemother. 2016. PMID: 27021341 Free article.
Tolerability of integrase inhibitors in a real-life setting.
Peñafiel J, de Lazzari E, Padilla M, Rojas J, Gonzalez-Cordon A, Blanco JL, Blanch J, Marcos MA, Lonca M, Martinez-Rebollar M, Laguno M, Tricas A, Rodriguez A, Mallolas J, Gatell JM, Martinez E. Peñafiel J, et al. Among authors: rojas j. J Antimicrob Chemother. 2017 Jun 1;72(6):1752-1759. doi: 10.1093/jac/dkx053. J Antimicrob Chemother. 2017. PMID: 28333231
Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis.
Inciarte A, Leal L, González E, León A, Lucero C, Mallolas J, Torres B, Laguno M, Rojas J, Martínez-Rebollar M, González-Cordón A, Cruceta A, Arnaiz JA, Gatell JM, García F; STRIBPEP Study Group. Inciarte A, et al. Among authors: rojas j. J Antimicrob Chemother. 2017 Oct 1;72(10):2857-2861. doi: 10.1093/jac/dkx246. J Antimicrob Chemother. 2017. PMID: 29091217 Clinical Trial.
1,371 results